| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.942 | 0.002 | 0.942 | Alpha adrenoreceptor agonist | 0.662 0.003 DBMET00464 0.715 0.003 DBMET00465 | ||
| 0.935 | 0.001 | 0.935 | Alpha 2 adrenoreceptor agonist | 0.635 0.002 DBMET00464 0.671 0.002 DBMET00465 | ||
| 0.853 | 0.001 | 0.853 | Alpha 2b adrenoreceptor agonist | 0.326 0.002 DBMET00464 0.243 0.002 DBMET00465 | ||
| 0.766 | 0.001 | 0.766 | Alpha 2c adrenoreceptor agonist | 0.205 0.002 DBMET00464 0.134 0.002 DBMET00465 | ||
| 0.738 | 0.001 | 0.738 | Alpha 2a adrenoreceptor agonist | 0.391 0.001 DBMET00464 0.404 0.001 DBMET00465 | ||
| 0.733 | 0.004 | 0.733 | Antiadrenergic | 0.569 0.005 DBMET00464 0.544 0.005 DBMET00465 | ||
| 0.731 | 0.004 | 0.731 | Adrenaline antagonist | 0.566 0.005 DBMET00464 0.542 0.005 DBMET00465 | ||
| 0.682 | 0.003 | 0.682 | Alpha 2a adrenoreceptor antagonist | 0.366 0.005 DBMET00464 0.333 0.005 DBMET00465 | ||
| 0.652 | 0.003 | 0.652 | Alpha 2b adrenoreceptor antagonist | 0.403 0.005 DBMET00464 0.357 0.006 DBMET00465 | ||
| 0.628 | 0.002 | 0.628 | Prostacyclin antagonist | 0.403 0.003 DBMET00464 0.417 0.003 DBMET00465 | ||
| 0.606 | 0.004 | 0.606 | Alpha 2 adrenoreceptor antagonist | 0.301 0.008 DBMET00464 0.267 0.01 DBMET00465 | ||
| 0.55 | 0.003 | 0.55 | Alpha 2c adrenoreceptor antagonist | 0.313 0.006 DBMET00464 0.292 0.007 DBMET00465 | ||
| 0.509 | 0.001 | 0.509 | Alpha 2d adrenoreceptor agonist | 0.424 0.001 DBMET00464 0.407 0.001 DBMET00465 | ||
| 0.505 | 0.031 | 0.505 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.47 0.049 DBMET00464 0.326 0.179 DBMET00465 | ||
| 0.461 | 0.001 | 0.461 | Alpha 1b adrenoreceptor agonist | 0.346 0.001 DBMET00464 0.339 0.001 DBMET00465 | ||
| 0.422 | 0.004 | 0.422 | Alpha 1 adrenoreceptor agonist | 0.18 0.007 DBMET00464 0.161 0.009 DBMET00465 | ||
| 0.344 | 0.012 | 0.344 | Alpha adrenoreceptor antagonist | 0.236 0.022 DBMET00464 0.154 0.037 DBMET00465 | ||
| 0.385 | 0.058 | 0.385 | Angiogenesis inhibitor | 0.308 0.089 DBMET00464 0.194 0.177 DBMET00465 | ||
| 0.314 | 0.003 | 0.314 | Vitronectin receptor antagonist | 0.178 0.004 DBMET00464 0.286 0.003 DBMET00465 | ||
| 0.317 | 0.022 | 0.317 | MAP-kinase-activated kinase 5 inhibitor | 0.276 0.044 DBMET00464 0.285 0.038 DBMET00465 | ||
| 0.274 | 0.004 | 0.274 | Adrenaline agonist | 0.234 0.005 DBMET00464 0.265 0.004 DBMET00465 | ||
| 0.286 | 0.028 | 0.305 | Src kinase inhibitor | 0.305 0.025 DBMET00464 0.145 0.087 DBMET00465 | DBMET00464 | |
| 0.277 | 0.02 | 0.277 | Lck kinase inhibitor | 0.181 0.049 DBMET00464 0.142 0.071 DBMET00465 | ||
| 0.253 | 0.002 | 0.253 | Alpha 1a adrenoreceptor agonist | 0.206 0.002 DBMET00464 0.196 0.002 DBMET00465 | ||
| 0.299 | 0.051 | 0.299 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.252 0.067 DBMET00464 0.187 0.101 DBMET00465 | ||
| 0.296 | 0.054 | 0.296 | Dyrk kinase inhibitor | 0.249 0.072 DBMET00464 0.173 0.116 DBMET00465 | ||
| 0.262 | 0.023 | 0.262 | Bone formation stimulant | 0.191 0.038 DBMET00464 0.228 0.029 DBMET00465 | ||
| 0.251 | 0.029 | 0.251 | Protein-tyrosine kinase Lyn inhibitor | 0.156 0.063 DBMET00464 0.106 0.097 DBMET00465 | ||
| 0.224 | 0.012 | 0.224 | Alpha 1b adrenoreceptor antagonist | 0.175 0.018 DBMET00464 0.124 0.028 DBMET00465 | ||
| 0.192 | 0.01 | 0.192 | Alpha 1d adrenoreceptor antagonist | 0.134 0.017 DBMET00464 0.086 0.028 DBMET00465 | ||
| 0.22 | 0.055 | 0.22 | I kappa B kinase epsilon inhibitor | 0.207 0.065 DBMET00464 | ||
| 0.201 | 0.042 | 0.201 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.155 0.07 DBMET00464 | ||
| 0.19 | 0.035 | 0.19 | Protein kinase (CK1) gamma 2 inhibitor | 0.115 0.069 DBMET00464 | ||
| 0.177 | 0.024 | 0.177 | Alpha 1 adrenoreceptor antagonist | 0.123 0.036 DBMET00464 0.068 0.06 DBMET00465 | ||
| 0.175 | 0.029 | 0.177 | Aurora-C kinase inhibitor | 0.177 0.028 DBMET00464 0.175 0.029 DBMET00465 | DBMET00464 | |
| 0.162 | 0.019 | 0.162 | Insulin growth factor antagonist | 0.109 0.041 DBMET00464 | ||
| 0.189 | 0.048 | 0.189 | Protein kinase (CK1) gamma inhibitor | 0.124 0.086 DBMET00464 | ||
| 0.141 | 0.003 | 0.141 | Integrin alphaVbeta1 antagonist | 0.072 0.004 DBMET00464 0.067 0.004 DBMET00465 | ||
| 0.139 | 0.002 | 0.139 | Alpha 1L adrenoreceptor agonist | 0.115 0.002 DBMET00464 0.135 0.002 DBMET00465 | ||
| 0.155 | 0.019 | 0.155 | Insulin like growth factor 1 antagonist | 0.103 0.04 DBMET00464 | ||
| 0.177 | 0.045 | 0.177 | Cyclin-dependent kinase inhibitor | 0.154 0.054 DBMET00464 0.109 0.082 DBMET00465 | ||
| 0.136 | 0.004 | 0.136 | Integrin alphaVbeta3 antagonist | 0.071 0.004 DBMET00464 0.123 0.004 DBMET00465 | ||
| 0.135 | 0.014 | 0.135 | Alpha 2d adrenoreceptor antagonist | 0.107 0.038 DBMET00464 0.09 0.072 DBMET00465 | ||
| 0.12 | 0.001 | 0.12 | Integrin beta6 antagonist | 0.066 0.002 DBMET00464 0.084 0.002 DBMET00465 | ||
| 0.298 | 0.182 | 0.298 | MAP kinase 1 inhibitor | |||
| 0.129 | 0.014 | 0.133 | CXC chemokine receptor antagonist | 0.133 0.014 DBMET00464 0.1 0.024 DBMET00465 | DBMET00464 | |
| 0.131 | 0.02 | 0.131 | 5 Hydroxytryptamine 7 antagonist | 0.083 0.03 DBMET00464 | ||
| 0.169 | 0.062 | 0.185 | Cyclin-dependent kinase 3 inhibitor | 0.185 0.044 DBMET00464 | DBMET00464 | |
| 0.11 | 0.002 | 0.11 | Imidazoline I1 receptor antagonist | 0.037 0.005 DBMET00464 0.036 0.005 DBMET00465 | ||
| 0.117 | 0.012 | 0.117 | NMDA 2B receptor antagonist | 0.076 0.022 DBMET00464 | ||
| 0.27 | 0.167 | 0.27 | MAP kinase kinase 6 inhibitor | 0.249 0.191 DBMET00464 0.235 0.21 DBMET00465 | ||
| 0.155 | 0.052 | 0.228 | c-Src kinase inhibitor | 0.228 0.029 DBMET00464 | DBMET00464 | |
| 0.164 | 0.061 | 0.164 | Growth factor antagonist | 0.123 0.089 DBMET00464 | ||
| 0.133 | 0.047 | 0.133 | Interleukin 8 antagonist | |||
| 0.11 | 0.024 | 0.11 | Nicotinic alpha4beta2 receptor antagonist | |||
| 0.124 | 0.039 | 0.124 | CDK2/cyclin A inhibitor | 0.118 0.044 DBMET00464 | ||
| 0.187 | 0.105 | 0.208 | ErbB-1 antagonist | 0.208 0.081 DBMET00464 | DBMET00464 | |
| 0.164 | 0.083 | 0.164 | Tyrosine kinase inhibitor | 0.155 0.087 DBMET00464 | ||
| 0.091 | 0.012 | 0.124 | Potassium channel (Ca-activated) blocker | 0.063 0.036 DBMET00464 0.124 0.006 DBMET00465 | DBMET00465 | |
| 0.174 | 0.095 | 0.174 | Focal adhesion kinase 2 inhibitor | 0.152 0.128 DBMET00464 | ||
| 0.12 | 0.041 | 0.12 | CDK/cyclin complex inhibitor | 0.1 0.052 DBMET00464 | ||
| 0.147 | 0.07 | 0.147 | Protein kinase (CK1) inhibitor | 0.107 0.102 DBMET00464 | ||
| 0.092 | 0.014 | 0.092 | Cyclin B1 inhibitor | 0.077 0.025 DBMET00464 | ||
| 0.131 | 0.055 | 0.131 | Protein kinase (CK2) alpha inhibitor | |||
| 0.077 | 0.005 | 0.077 | Dopamine beta hydroxylase inhibitor | 0.046 0.04 DBMET00465 | ||
| 0.105 | 0.034 | 0.105 | Alpha 1a adrenoreceptor antagonist | 0.074 0.048 DBMET00464 | ||
| 0.159 | 0.089 | 0.159 | Phospholipase C inhibitor | 0.153 0.1 DBMET00465 | ||
| 0.081 | 0.014 | 0.081 | Cyclin B2 inhibitor | 0.07 0.021 DBMET00464 0.051 0.045 DBMET00465 | ||
| 0.113 | 0.047 | 0.113 | Protein kinase C mu inhibitor | |||
| 0.093 | 0.027 | 0.093 | CDC7 inhibitor | 0.075 0.039 DBMET00464 | ||
| 0.116 | 0.051 | 0.116 | Protein kinase (CK2) inhibitor | 0.083 0.079 DBMET00464 | ||
| 0.164 | 0.1 | 0.164 | Anesthetic general | |||
| 0.232 | 0.169 | 0.232 | Calcium channel activator | |||
| 0.107 | 0.048 | 0.256 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.256 0.012 DBMET00464 | DBMET00464 | |
| 0.094 | 0.035 | 0.094 | Focal adhesion kinase 1 inhibitor | 0.08 0.049 DBMET00464 | ||
| 0.071 | 0.012 | 0.071 | Potassium channel small-conductance Ca-activated blocker | |||
| 0.088 | 0.03 | 0.088 | Neuronal nicotinic receptor antagonist | 0.074 0.042 DBMET00464 | ||
| 0.075 | 0.018 | 0.075 | Cyclin B inhibitor | 0.064 0.027 DBMET00464 | ||
| 0.114 | 0.058 | 0.114 | Cyclin-dependent kinase 1 inhibitor | 0.107 0.062 DBMET00464 0.086 0.077 DBMET00465 | ||
| 0.084 | 0.029 | 0.084 | ZAP-70 protein tyrosine kinase inhibitor | |||
| 0.092 | 0.037 | 0.259 | Raf kinase inhibitor | 0.259 0.009 DBMET00464 | DBMET00464 | |
| 0.113 | 0.062 | 0.113 | Activin receptor-like kinase 4 inhibitor | |||
| 0.112 | 0.063 | 0.112 | 5 Hydroxytryptamine 3A agonist | |||
| 0.131 | 0.082 | 0.131 | Protein kinase C nu inhibitor | |||
| 0.109 | 0.061 | 0.109 | CDC-like kinase 3 inhibitor | 0.102 0.075 DBMET00464 | ||
| 0.097 | 0.049 | 0.097 | Histamine N-methyltransferase inhibitor | |||
| 0.079 | 0.032 | 0.079 | 5 Hydroxytryptamine 3A antagonist | |||
| 0.068 | 0.022 | 0.068 | Nicotinic receptor alpha7 subunit antagonist | |||
| 0.135 | 0.089 | 0.156 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.156 0.073 DBMET00464 | DBMET00464 | |
| 0.077 | 0.031 | 0.077 | Potassium channel (ATP-sensitive) blocker | |||
| 0.049 | 0.005 | 0.132 | Integrin beta5 antagonist | 0.034 0.008 DBMET00464 0.132 0.004 DBMET00465 | DBMET00465 | |
| 0.271 | 0.227 | 0.271 | Caspase 9 stimulant | |||
| 0.107 | 0.063 | 0.107 | Cyclin-dependent kinase 2 inhibitor | 0.093 0.078 DBMET00464 | ||
| 0.047 | 0.003 | 0.047 | Complement factor 1r inhibitor | 0.042 0.004 DBMET00464 0.041 0.004 DBMET00465 | ||
| 0.063 | 0.02 | 0.063 | Nicotinic receptor alpha4 subunit antagonist | 0.063 0.02 DBMET00464 | ||
| 0.091 | 0.048 | 0.091 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.091 0.048 DBMET00464 | ||
| 0.129 | 0.088 | 0.129 | Protein kinase (CK1) gamma 1 inhibitor | |||
| 0.116 | 0.077 | 0.116 | Epidermal growth factor receptor kinase inhibitor | |||
| 0.088 | 0.05 | 0.088 | ALK inhibitor | |||
| 0.135 | 0.097 | 0.135 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.107 | 0.07 | 0.107 | Glycogen synthase kinase-3 beta inhibitor | |||
| 0.092 | 0.055 | 0.092 | Pim-3 kinase inhibitor | 0.079 0.078 DBMET00464 | ||
| 0.101 | 0.065 | 0.101 | Gastric antisecretory | |||
| 0.088 | 0.052 | 0.088 | TIE antagonist | |||
| 0.086 | 0.051 | 0.086 | TIE-2 antagonist | |||
| 0.105 | 0.07 | 0.105 | EphA2 antagonist | |||
| 0.119 | 0.085 | 0.119 | Glycogen synthase kinase-3 alpha inhibitor | 0.108 0.096 DBMET00464 | ||
| 0.107 | 0.073 | 0.107 | Glycogen synthase kinase-3 inhibitor | |||
| 0.049 | 0.019 | 0.054 | Integrin alpha5beta1 antagonist | 0.038 0.032 DBMET00464 0.054 0.015 DBMET00465 | DBMET00465 | |
| 0.15 | 0.12 | 0.15 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | |||
| 0.066 | 0.038 | 0.093 | Raf kinase C inhibitor | 0.093 0.027 DBMET00464 | DBMET00464 | |
| 0.056 | 0.028 | 0.056 | CXC chemokine 1 receptor antagonist | 0.052 0.033 DBMET00465 | ||
| 0.062 | 0.034 | 0.062 | Cyclin A1 inhibitor | 0.057 0.046 DBMET00464 | ||
| 0.081 | 0.053 | 0.081 | Acetylcholine nicotinic antagonist | |||
| 0.092 | 0.065 | 0.107 | Pim-1 kinase inhibitor | 0.107 0.051 DBMET00464 | DBMET00464 | |
| 0.093 | 0.066 | 0.093 | MAP kinase kinase 1 inhibitor | |||
| 0.034 | 0.008 | 0.049 | Integrin beta3 antagonist | 0.018 0.016 DBMET00464 0.049 0.006 DBMET00465 | DBMET00465 | |
| 0.132 | 0.107 | 0.24 | Polo-like kinase-3 inhibitor | 0.24 0.028 DBMET00464 | DBMET00464 | |
| 0.172 | 0.147 | 0.18 | Nitric-oxide synthase stimulant | 0.18 0.127 DBMET00464 | DBMET00464 | |
| 0.029 | 0.004 | 0.029 | Complement factor 1 inhibitor | 0.022 0.006 DBMET00464 0.022 0.006 DBMET00465 | ||
| 0.028 | 0.003 | 0.028 | Imidazoline I2 receptor antagonist | |||
| 0.062 | 0.039 | 0.062 | Cyclin D1 inhibitor | |||
| 0.033 | 0.009 | 0.033 | Thymidine phosphorylase inhibitor | 0.026 0.019 DBMET00464 0.026 0.018 DBMET00465 | ||
| 0.08 | 0.058 | 0.08 | Leucine-rich repeat kinase 2 inhibitor | |||
| 0.068 | 0.047 | 0.084 | Cyclin B3 inhibitor | 0.084 0.036 DBMET00464 | DBMET00464 | |
| 0.037 | 0.016 | 0.037 | Protein kinase (CK2) beta inhibitor | 0.031 0.03 DBMET00464 0.033 0.023 DBMET00465 | ||
| 0.117 | 0.1 | 0.117 | Activin receptor-like kinase 2 inhibitor | |||
| 0.052 | 0.034 | 0.052 | H+/K+-transporting ATPase inhibitor | |||
| 0.045 | 0.028 | 0.045 | Histamine H1 receptor agonist | |||
| 0.06 | 0.046 | 0.06 | Cyclin A2 inhibitor | |||
| 0.075 | 0.062 | 0.084 | Platelet growth factor antagonist | 0.084 0.053 DBMET00464 | DBMET00464 | |
| 0.088 | 0.076 | 0.088 | Aurora-A kinase inhibitor | |||
| 0.03 | 0.018 | 0.03 | MAP3K8 inhibitor | |||
| 0.174 | 0.163 | 0.174 | DNA synthesis inhibitor | |||
| 0.066 | 0.055 | 0.066 | NMDA 2 receptor antagonist | |||
| 0.029 | 0.019 | 0.029 | Nicotinic alpha4beta2 receptor agonist | |||
| 0.085 | 0.075 | 0.085 | Platelet activating factor beta antagonist | |||
| 0.015 | 0.006 | 0.015 | Cyclin D2 inhibitor | 0.014 0.008 DBMET00464 | ||
| 0.094 | 0.085 | 0.094 | 5 Hydroxytryptamine antagonist | |||
| 0.086 | 0.077 | 0.086 | Check point kinase 2 inhibitor | 0.086 0.078 DBMET00464 | ||
| 0.146 | 0.139 | 0.146 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.054 | 0.047 | 0.054 | CDK4/cyclin D inhibitor | |||
| 0.059 | 0.053 | 0.059 | Cyclin-dependent kinase 4 inhibitor | |||
| 0.056 | 0.05 | 0.056 | CDK1/cyclin B inhibitor | |||
| 0.206 | 0.201 | 0.206 | GABA C receptor rho-3 antagonist | |||
| 0.036 | 0.031 | 0.036 | Potassium channel Kv1.1 blocker | |||
| 0.083 | 0.08 | 0.111 | DNA directed RNA polymerase inhibitor | 0.111 0.045 DBMET00464 | DBMET00464 | |
| 0.016 | 0.013 | 0.016 | Nicotinic alpha4 receptor agonist | |||
| 0.037 | 0.035 | 0.037 | Thymidine kinase inhibitor | |||
| 0.035 | 0.033 | 0.035 | Alpha 1d adrenoreceptor agonist | |||
| 0.084 | 0.083 | 0.084 | MAP kinase 8 inhibitor | |||
| 0.013 | 0.012 | 0.013 | Integrin alphaVbeta6 antagonist | 0.013 0.011 DBMET00465 | ||
| 0.034 | 0.034 | 0.049 | Integrin antagonist | 0.049 0.028 DBMET00465 | DBMET00465 | |
| 0.026 | 0.027 | 0.029 | DNA polymerase III inhibitor | 0.029 0.018 DBMET00465 | DBMET00465 | |
| 0.024 | 0.026 | 0.025 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.025 0.023 DBMET00464 | DBMET00464 | |
| 0.099 | 0.101 | 0.289 | MAP kinase 12 inhibitor | 0.289 0.008 DBMET00464 | DBMET00464 | |
| 0.071 | 0.076 | 0.086 | MAP-kinase-activated kinase inhibitor | 0.086 0.054 DBMET00464 | DBMET00464 | |
| 0.018 | 0.023 | 0.02 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.02 0.016 DBMET00464 | DBMET00464 | |
| 0.189 | 0.202 | 0.203 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.203 0.158 DBMET00464 0.196 0.176 DBMET00465 | DBMET00464 | |
| 0.06 | 0.077 | 0.075 | MAP-kinase-activated kinase 2 inhibitor | 0.075 0.05 DBMET00464 | DBMET00464 | |
| 0.173 | 0.193 | 0.217 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.217 0.138 DBMET00464 | DBMET00464 | |
| 0.039 | 0.069 | 0.162 | Raf kinase B inhibitor | 0.162 0.012 DBMET00464 | DBMET00464 | |
| 0.062 | 0.097 | 0.139 | NMDA receptor antagonist | 0.139 0.028 DBMET00465 | DBMET00465 | |
| 0.104 | 0.165 | 0.137 | Clk dual-specificity kinase inhibitor | 0.137 0.127 DBMET00464 | DBMET00464 | |
| 0.009 | 0.084 | 0.06 | Kainate receptor 4 antagonist | 0.06 0.005 DBMET00465 | DBMET00465 | |
| 0.09 | 0.172 | 0.129 | CDC-like kinase 4 inhibitor | 0.129 0.119 DBMET00464 | DBMET00464 | |
| 0.057 | 0.146 | 0.095 | Polo-like kinase-4 inhibitor | 0.095 0.082 DBMET00464 | DBMET00464 | |
| 0.1 | 0.206 | 0.122 | Death-associated protein kinase 1 inhibitor | 0.122 0.107 DBMET00464 | DBMET00464 | |
| 0.007 | 0.114 | 0.026 | Kainate receptor 3 antagonist | 0.026 0.006 DBMET00465 | DBMET00465 | |
| 0.006 | 0.123 | 0.038 | Kainate receptor 5 antagonist | 0.038 0.007 DBMET00465 | DBMET00465 | |
| 0.055 | 0.184 | 0.145 | Glutamate receptor antagonist | 0.109 0.086 DBMET00464 0.145 0.054 DBMET00465 | DBMET00465 | |
| 0.095 | 0.23 | 0.162 | Platelet aggregation inhibitor | 0.162 0.115 DBMET00464 | DBMET00464 | |
| 0.106 | 0.253 | 0.177 | Death-associated protein kinase 2 inhibitor | 0.177 0.058 DBMET00464 0.153 0.099 DBMET00465 | DBMET00464 | |
| 0.025 | 0.204 | 0.147 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | 0.147 0.015 DBMET00464 | DBMET00464 | |
| 0.007 | 0.209 | 0.051 | AMPA 2 receptor antagonist | 0.051 0.011 DBMET00465 | DBMET00465 | |
| 0.025 | 0.529 | 0.188 | Interleukin antagonist | 0.188 0.091 DBMET00464 | DBMET00464 | |
| 0.014 | 0.858 | 0.317 | Interleukin 5 antagonist | 0.317 0.004 DBMET00464 | DBMET00464 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |